Tags

Type your tag names separated by a space and hit enter

Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease.
Kidney Int. 2013 May; 83(5):909-14.KI

Abstract

Novel biomarkers may improve our ability to predict which patients with chronic kidney disease (CKD) are at higher risk for progressive loss of renal function. Here, we assessed the performance of urine neutrophil gelatinase-associated lipocalin (NGAL) for outcome prediction in a diverse cohort of 3386 patients with CKD in the Chronic Renal Insufficiency Cohort study. In this cohort, the baseline mean estimated glomerular filtration rate (eGFR) was 42.4 ml/min per 1.73 m(2), the median 24-h urine protein was 0.2 g/day, and the median urine NGAL concentration was 17.2 ng/ml. Over an average follow-up of 3.2 years, there were 689 cases in which the eGFR was decreased by half or incident end-stage renal disease developed. Even after accounting for eGFR, proteinuria, and other known CKD progression risk factors, urine NGAL remained a significant independent risk factor (Cox model hazard ratio 1.70 highest to lowest quartile). The association between baseline urine NGAL levels and risk of CKD progression was strongest in the first 2 years of biomarker measurement. Within this time frame, adding urine NGAL to a model that included eGFR, proteinuria, and other CKD progression risk factors led to net reclassification improvement of 24.7%, but the C-statistic remained nearly identical. Thus, while urine NGAL was an independent risk factor of progression among patients with established CKD of diverse etiology, it did not substantially improve prediction of outcome events.

Authors+Show Affiliations

Division of Nephrology, University of California, San Francisco, San Francisco, California, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

23344473

Citation

Liu, Kathleen D., et al. "Urine Neutrophil Gelatinase-associated Lipocalin Levels Do Not Improve Risk Prediction of Progressive Chronic Kidney Disease." Kidney International, vol. 83, no. 5, 2013, pp. 909-14.
Liu KD, Yang W, Anderson AH, et al. Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int. 2013;83(5):909-14.
Liu, K. D., Yang, W., Anderson, A. H., Feldman, H. I., Demirjian, S., Hamano, T., He, J., Lash, J., Lustigova, E., Rosas, S. E., Simonson, M. S., Tao, K., & Hsu, C. Y. (2013). Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney International, 83(5), 909-14. https://doi.org/10.1038/ki.2012.458
Liu KD, et al. Urine Neutrophil Gelatinase-associated Lipocalin Levels Do Not Improve Risk Prediction of Progressive Chronic Kidney Disease. Kidney Int. 2013;83(5):909-14. PubMed PMID: 23344473.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. AU - Liu,Kathleen D, AU - Yang,Wei, AU - Anderson,Amanda H, AU - Feldman,Harold I, AU - Demirjian,Sevag, AU - Hamano,Takayuki, AU - He,Jiang, AU - Lash,James, AU - Lustigova,Eva, AU - Rosas,Sylvia E, AU - Simonson,Michael S, AU - Tao,Kaixiang, AU - Hsu,Chi-yuan, AU - ,, Y1 - 2013/01/23/ PY - 2013/1/25/entrez PY - 2013/1/25/pubmed PY - 2013/11/20/medline SP - 909 EP - 14 JF - Kidney international JO - Kidney Int VL - 83 IS - 5 N2 - Novel biomarkers may improve our ability to predict which patients with chronic kidney disease (CKD) are at higher risk for progressive loss of renal function. Here, we assessed the performance of urine neutrophil gelatinase-associated lipocalin (NGAL) for outcome prediction in a diverse cohort of 3386 patients with CKD in the Chronic Renal Insufficiency Cohort study. In this cohort, the baseline mean estimated glomerular filtration rate (eGFR) was 42.4 ml/min per 1.73 m(2), the median 24-h urine protein was 0.2 g/day, and the median urine NGAL concentration was 17.2 ng/ml. Over an average follow-up of 3.2 years, there were 689 cases in which the eGFR was decreased by half or incident end-stage renal disease developed. Even after accounting for eGFR, proteinuria, and other known CKD progression risk factors, urine NGAL remained a significant independent risk factor (Cox model hazard ratio 1.70 highest to lowest quartile). The association between baseline urine NGAL levels and risk of CKD progression was strongest in the first 2 years of biomarker measurement. Within this time frame, adding urine NGAL to a model that included eGFR, proteinuria, and other CKD progression risk factors led to net reclassification improvement of 24.7%, but the C-statistic remained nearly identical. Thus, while urine NGAL was an independent risk factor of progression among patients with established CKD of diverse etiology, it did not substantially improve prediction of outcome events. SN - 1523-1755 UR - https://www.unboundmedicine.com/medline/citation/23344473/Urine_neutrophil_gelatinase_associated_lipocalin_levels_do_not_improve_risk_prediction_of_progressive_chronic_kidney_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0085-2538(15)55821-3 DB - PRIME DP - Unbound Medicine ER -